Chemed Corporation

NYSE:CHE

Medical - Care Facilities

Healthcare
$546.72 +1.13%

+$4.91 today

Market cap
$7.12B
Beta
0.54
P/E (TTM)
23.2
EPS (TTM)
$19.00
Dividend yield
0.54%
52W Low $365.21High $562.77

Volume 0.17M

Average 0.25M

CHE Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Chemed CorporationNYSE: CHE

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures dips below year-ago levels

Q2 FY2026 capital expenditures of $15.52M (cash outflow) fell 1.8% year over year, behind the +19.8% change in trailing-twelve-month capital expenditures. Sequentially, it fell 9.3% from the prior quarter. Over 3 fiscal years it compounded at +3.1% a year.

Context

  • Capital expenditures amounted to 2.5% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -1.8% toward the trailing-twelve-month pace of +19.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$15.52M-9.3% QoQ
Last fiscal yearDec 2025
-$62.8M+26.8% YoY
LTMJun 2026
-$66.35M+19.8% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.8%——
1 year+26.8%——
3-year CAGR+3.1%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(62.8M) USD
Year-over-year change
-26.8%

Capital Expenditures vs competitors

How CHE compares with its peers on the latest reported figures

  • CHE's LTM Jun 2026 capital expenditures of $66.35M is the largest of the 5 companies compared; the peer median is $14.24M.
  • Its year-over-year change of +19.8% is the lowest of 5, against a peer median of +75.6%.
  • Capital expenditures amounts to 2.6% of revenue for CHE, versus a peer median of 0.5%.
CHE Competitors Peer median
Capital Expenditures for CHE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHEChemed CorporationLTM Jun 2026$66.35M +19.8%+3.1%2.6%
OPCHOption Care Health, Inc.LTM Sep 2026$25.15M +143.2%+5.3%0.4%
PNTGThe Pennant Group, Inc.LTM Mar 2026$18.77M +113.1%+15.8%1.8%
AVAHAveanna Healthcare Holdings Inc.LTM Oct 2026$9.7M +38.1%-14.7%0.4%
ADUSAddus HomeCare CorporationLTM Jun 2026$9.34M +38.1%-2.4%0.6%
Peer median (excluding CHE) $14.24M+75.6%+1.5%0.5%

Competitors are the stored peer set for CHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income268.55M249.62M272.51M302M265.24M
Depreciation & Amortization59.05M59.17M60.87M63.05M64.84M
Deferred Income Tax(15.78M)(3.35M)(8.03M)(4.14M)(5.94M)
Stock-Based Compensation22.5M26.25M30.08M32.03M4.89M
Change in Working Capital(26.8M)(33.49M)(39.31M)8.13M23.71M
Accounts Receivables(8.43M)(2.41M)(41.49M)10.68M(11.6M)
Inventory(3.01M)(162K)(1.73M)3.83M650K
Accounts Payables9.83M15.34M(9.35M)(9.28M)(5.19M)
Other Working Capital(25.19M)(46.26M)13.26M2.9M39.85M
Other Non-Cash Items1.07M11.67M14.18M16.42M35.54M
Operating Cash Flow308.6M309.89M330.3M417.5M388.27M
Capital Expenditures(58.68M)(57.33M)(56.85M)(49.53M)(62.8M)
Acquisitions (Net)0(3.53M)(3.99M)(97.4M)(225K)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities918K1.45M206K3.02M3.68M
Investing Cash Flow(57.76M)(59.4M)(60.64M)(143.91M)(59.34M)
Debt Repayment196.88M(99.38M)(81.75M)(15.75M)10.97M
Common Stock Issued000027.15M
Common Stock Repurchased(576.04M)(114.52M)(67.7M)(361.39M)(431.5M)
Dividends Paid(22.02M)(22.02M)(23.5M)(27.09M)(31.7M)
Other Financing Activities20.55M26.66M93.13M45.04M(7.69M)
Financing Cash Flow(380.62M)(209.25M)(79.83M)(359.19M)(432.77M)
Effect of Forex Changes00000
Net Change in Cash(129.78M)41.23M189.83M(85.61M)(103.84M)
Free Cash Flow249.92M252.56M273.45M367.97M325.48M

Chemed Corporation

NYSE:CHE

Intrinsic Alpha fair value

Locked

Current Price

$546.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.